Pharmacokinetic Benefits of 3,4-Dimethoxy Substitution of a Phenyl Ring and Design of Isosteres Yielding Orally Available Cathepsin K Inhibitors
摘要:
Rational structure-based design has yielded highly potent inhibitors of cathepsin K (Cat K) with excellent physical properties, selectivity profiles, and pharmacokinetics. Compounds with a 3,4-(CH3O)(2)Ph motif, such as 31, were found to have excellent metabolic stability and absorption profiles. Through metabolite identification studies, a reactive metabolite risk was identified with this motif: Subsequent structure-based design of isoteres culminated in the discovery of an optimized and balanced inhibitor (indazole, 38).
超长链脂肪酸(VLCFA)是除草剂发现的最主要和最有希望的目标之一。为了探索和发现具有更高除草活性和改善作物安全性的新型VLCFAs抑制剂,使用了多种新的3-{[(5,5-二甲基-4-4,5-二氢异恶唑-3-基)磺酰基]甲基}苯并[d]对]异恶唑衍生物进行了合理的设计和合成。温室试验的结果表明,几种化合物以150 g ai / ha的速率对Digitaria sanguinalis,Echinochloa crus-galli和Setaria faberii表现出良好的除草活性。化合物g4和h1对D血红蛋白和C. crus-galli表现出有希望的除草活性剂量为75 g ai / ha,优于商业吡pyr砜和S-异丙甲草胺。此外,化合物H1显示对更高的活性Ë稗,d马唐和小号大狗尾草甚至在37.5 18.75 g的速度比,pyroxasulfone与S-异丙甲草胺成分/公顷。此外,化合物g4和
[EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET UTILISATIONS DE CES DERNIERS
申请人:YUMANITY THERAPEUTICS
公开号:WO2018081167A1
公开(公告)日:2018-05-03
The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
A switchable synthesis route is developed for benzo[d]oxazole derivatives and (2-hydroxylaryl)benzamide from 2-hydroxylbenzeneketoxime using organomolecules (BOP-Cl, and CNC) and Lewis acid cocatalyzed Beckmannrearrangement (BR) reaction. Further, this reaction is switched using different organocatalysts.
利用有机分子(BOP-Cl和CNC)和路易斯酸共催化的贝克曼重排(BR)反应,开发了可转换的合成路线,用于由2-羟基苯酮肟合成苯并[ d ]恶唑衍生物和(2-羟基芳基)苯甲酰胺。此外,使用不同的有机催化剂来切换该反应。
AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
申请人:Bahmanyar Sogole
公开号:US20100093698A1
公开(公告)日:2010-04-15
Provided herein are Heteroaryl Compounds of formula (I):
wherein R
1
and R
2
are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing inflammatory conditions or cancer, and conditions treatable or preventable by inhibition of a kinase or a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a subject in need thereof.